Literature DB >> 16720564

Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Su-Mi Choi, Dong-Gun Lee, Jung-Hyun Choi, Jin-Hong Yoo, Yoo-Jin Kim, Sun Hee Park, Chang-Ki Min, Seok Lee, Hee-Je Kim, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Wan-Shik Shin, Chun-Choo Kim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16720564     DOI： 10.1007/bf02985486

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  6 in total

1.  High variability between results of different in-house tests for cytomegalovirus (CMV) monitoring and a standardized quantitative plasma CMV PCR assay.

Authors:  Lutz Von Müller; Walter Hampl; Joachim Hinz; Helga Meisel; Angela Reip; Elisabeth Engelmann; Regine Heilbronn; Barbara Gärtner; Oliver Krämer; Hermann Einsele; Holger Hebart; Tatjana Ljubicic; Jürgen Löffler; Thomas Mertens
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  High-grade cytomegalovirus antigenemia after hematopoietic stem cell transplantation.

Authors:  Y Asano-Mori; K Oshima; M Sakata-Yanagimoto; M Nakagawa; K Kandabashi; K Izutsu; A Hangaishi; T Motokura; S Chiba; M Kurokawa; H Hirai; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

3.  Risk-adapted preemptive therapy for cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Yoshinobu Aisa; Tomonori Nakazato; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

4.  Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea.

Authors:  Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo; Yoo-Jin Kim; Sun Hee Park; Sun-Nam Park; Chang-Ki Min; Seok Lee; Hee-Je Kim; Dong-Wook Kim; Jong-Wook Lee; Woo-Sung Min; Wan-Shik Shin; Chun-Choo Kim
Journal:  Int J Hematol       Date:  2005-01       Impact factor: 2.490

5.  Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.

Authors:  T Mori; S Okamoto; S Matsuoka; T Yajima; M Wakui; R Watanabe; A Ishida; Y Iwao; M Mukai; T Hibi; Y Ikeda
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

6.  Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.

Authors:  Y Kanda; S Mineishi; T Saito; S Seo; A Saito; K Suenaga; M Ohnishi; H Niiya; K Nakai; T Takeuchi; N Kawahigashi; N Shoji; T Ogasawara; R Tanosaki; Y Kobayashi; K Tobinai; M Kami; S Mori; R Suzuki; H Kunitoh; Y Takaue
Journal:  Bone Marrow Transplant       Date:  2001-02       Impact factor: 5.483
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.